The estimated Net Worth of Megan Boston is at least $620 Tysiąc dollars as of 11 August 2023. Ms Boston owns over 25,907 units of Benitec Biopharma Inc stock worth over $218,655 and over the last 4 years she sold BNTC stock worth over $0. In addition, she makes $401,698 as Exec. Director at Benitec Biopharma Inc.
Sign up
Ms GAICD BNTC stock SEC Form 4 insiders trading
Ms has made over 1 trades of the Benitec Biopharma Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently she bought 25,907 units of BNTC stock worth $218,655 on 11 August 2023.
The largest trade she's ever made was buying 25,907 units of Benitec Biopharma Inc stock on 11 August 2023 worth over $218,655. On average, Ms trades about 6,477 units every 0 days since 2020. As of 11 August 2023 she still owns at least 25,907 units of Benitec Biopharma Inc stock.
You can see the complete history of Ms Boston stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Ms. Megan Joan Boston BComm, CA, Dip., GAICD biography
Megan Joan Boston BComm, CA, Dip., GAICD is the Exec. Director at Benitec Biopharma Inc.
What is the salary of Ms GAICD?
As the Exec. Director of Benitec Biopharma Inc, the total compensation of Ms GAICD at Benitec Biopharma Inc is $401,698. There are 1 executives at Benitec Biopharma Inc getting paid more, with Dr. Jerel A. Banks M.D., Ph.D. having the highest compensation of $697,688.
How old is Ms GAICD?
Ms GAICD is 49, she's been the Exec. Director of Benitec Biopharma Inc since . There are no older and 1 younger executives at Benitec Biopharma Inc.
What's Ms GAICD's mailing address?
Megan's mailing address filed with the SEC is C/O BENITEC BIOPHARMA INC., 3940 TRUST WAY, HAYWARD, CA, 94545.
Insiders trading at Benitec Biopharma Inc
Over the last 4 years, insiders at Benitec Biopharma Inc have traded over $0 worth of Benitec Biopharma Inc stock and bought 409,597 units worth $1,496,765 . The most active insiders traders include Steven Michael Oliveira, J Kevin Buchi oraz Edward F Smith. On average, Benitec Biopharma Inc executives and independent directors trade stock every 278 days with the average trade being worth of $1,152,330. The most recent stock trade was executed by J Kevin Buchi on 11 August 2023, trading 51,813 units of BNTC stock currently worth $437,302.
What does Benitec Biopharma Inc do?
benitec biopharma is using patented ‘gene-silencing’ technology to develop drugs for chronic and life-threatening human diseases. our transformational technology, ddrnai, targets and ‘turns off’ specific genes related to disease, providing lasting treatment and potentially cure with a single dose. compared to traditional approaches to rna intereference, ddrnai is easier to deliver, safer to us, more targeted and more efficient. benitec has a pipeline of in-house and partnered drug development programs based on ddrnai, including hepatitis c and b and cancer-associated pain. ddrnai has the potential to silence genes related to thousands of human diseases and is protected by over 40 global patents. the technology is available from benitec under a variety of licence options.
What does Benitec Biopharma Inc's logo look like?
Complete history of Ms Boston stock trades at Benitec Biopharma Inc
Benitec Biopharma Inc executives and stock owners
Benitec Biopharma Inc executives and other stock owners filed with the SEC include:
-
Dr. Jerel A. Banks M.D., Ph.D.,
CEO & Exec. Chairman -
Megan Joan Boston BComm, CA, Dip., GAICD,
Exec. Director -
Dr. Claudia Kloth,
Sr. VP of Manufacturing -
Dr. Craig Lewis,
Chief Medical Adviser -
Dr. Michael Graham,
Head of Discovery & Founding Scientist -
Bryan Dulhunty,
Chief Financial Officer -
Edward F Smith,
Director -
Megan Boston,
Executive Director -
Jerel A. Banks,
Chief Executive Officer -
Peter Francis,
Director -
Steven Michael Oliveira,
10% owner -
J Kevin Buchi,
Director